|
1
|
Sugitani I, Miyauchi A, Sugino K, Okamoto
T, Yoshida A and Suzuki S: Prognostic factors and treatment
outcomes for anaplastic thyroid carcinoma: ATC Research Consortium
of Japan cohort study of 677 patients. World J Surg. 36:1247–1254.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kebebew E, Greenspan FS, Clark OH, Woeber
KA and McMillan A: Anaplastic thyroid carcinoma. Treatment outcome
and prognostic factors. Cancer. 103:1330–1335. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Haymart MR, Banerjee M, Yin H, Worden F
and Griggs JJ: Marginal treatment benefit in anaplastic thyroid
cancer. Cancer. 119:3133–3139. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Smallridge RC, Ain KB, Asa SL, Bible KC,
Brierley JD, Burman KD, Kebebew E, Lee NY, Nikiforov YE, Rosenthal
MS, et al; American Thyroid Association Anaplastic Thyroid Cancer
Guidelines Taskforce. American Thyroid Association guidelines for
management of patients with anaplastic thyroid cancer. Thyroid.
22:1104–1139. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sugino K and Onoda N: Part VII. Anaplastic
carcinoma. Treatment of Thyroid cancer. Japanese Clinical
Guidelines. Takami H, Ito Y, Noguchi H, Yoshida A and Okamoto T:
Springer; Japan, Tokyo: pp. 203–230. 2012
|
|
6
|
Haugen BR and Sherman SI: Evolving
approaches to patients with advanced differentiated thyroid cancer.
Endocr Rev. 34:439–455. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Onoda N, Ito Y, Ito K, Sugitani I,
Takahashi S, Yamaguchi I, Kawakami Y and Tsukada K: Phase II
clinical trial of sorafenib in Japanese patients with anaplastic
thyroid carcinoma and locally advanced or metastatic medullary
thyroid carcinoma. Thyroid. 25:A1202015.
|
|
8
|
Takahashi S, Tahara M, Kiyota N, Yamazaki
T, Chayahara N, Nakano K, Inagaki R, Toda K, Enokida T, Minami H,
et al: Phase II study of lenvatinib, a multi-targeted tyrosine
kinase inhibitor, in patients with all histologic subtypes of
advanced thyroid cancer. Ann Oncol. 25(Suppl_4): iv340–iv356.
2014.
|
|
9
|
Rosove MH, Peddi PF and Glaspy JA: BRAF
V600E inhibition in anaplastic thyroid cancer. N Engl J Med.
368:684–685. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hyman DM, Puzanov I, Subbiah V, Faris JE,
Chau I, Blay JY, Wolf J, Raje NS, Diamond EL, Hollebecque A, et al:
Vemurafenib in multiple nonmelanoma cancers with BRAF V600
mutations. N Engl J Med. 373:726–736. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kim TH, Park YJ, Lim JA, Ahn HY, Lee EK,
Lee YJ, Kim KW, Hahn SK, Youn YK, Kim KH, et al: The association of
the BRAF(V600E) mutation with prognostic factors and poor clinical
outcome in papillary thyroid cancer: A meta-analysis. Cancer.
118:1764–1773. 2012. View Article : Google Scholar
|
|
12
|
Smallridge RC and Copland JA: Anaplastic
thyroid carcinoma: Pathogenesis and emerging therapies. Clin Oncol
(R Coll Radiol). 22:486–497. 2010. View Article : Google Scholar
|
|
13
|
Xing M: BRAF mutation in thyroid cancer.
Endocr Relat Cancer. 12:245–262. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang HM, Huang YW, Huang JS, Wang CH, Kok
VC, Hung CM, Chen HM and Tzen CY: Anaplastic carcinoma of the
thyroid arising more often from follicular carcinoma than papillary
carcinoma. Ann Surg Oncol. 14:3011–3018. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shi X, Liu R, Qu S, Zhu G, Bishop J, Liu
X, Sun H, Shan Z, Wang E, Luo Y, et al: Association of TERT
promoter mutation 1,295,228 C>T with BRAF V600E mutation, older
patient age, and distant metastasis in anaplastic thyroid cancer. J
Clin Endocrinol Metab. 100:E632–E637. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Onoda N, Nakamura M, Aomatsu N, Noda S,
Kashiwagi S and Hirakawa K: Establishment, characterization and
comparison of seven authentic anaplastic thyroid cancer cell lines
retaining clinical features of the original tumors. World J Surg.
38:688–695. 2014. View Article : Google Scholar
|
|
17
|
Nobuhara Y, Onoda N, Yamashita Y, Yamasaki
M, Ogisawa K, Takashima T, Ishikawa T and Hirakawa K: Efficacy of
epidermal growth factor receptor-targeted molecular therapy in
anaplastic thyroid cancer cell lines. Br J Cancer. 92:1110–1116.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Onoda N, Nakamura M, Aomatsu N, Noda S,
Kashiwagi S, Kurata K, Uchino S and Hirakawa K: Significant
cytostatic effect of everolimus on a gefitinib-resistant anaplastic
thyroid cancer cell line harboring PI3KCA gene mutation. Mol Clin
Oncol. 3:522–526. 2015.PubMed/NCBI
|
|
19
|
Salvatore G, De Falco V, Salerno P, Nappi
TC, Pepe S, Troncone G, Carlomagno F, Melillo RM, Wilhelm SM and
Santoro M: BRAF is a therapeutic target in aggressive thyroid
carcinoma. Clin Cancer Res. 12:1623–1629. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hou P, Liu D and Xing M: Genome-wide
alterations in gene methylation by the BRAF V600E mutation in
papillary thyroid cancer cells. Endocr Relat Cancer. 18:687–697.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jo YS, Li S, Song JH, Kwon KH, Lee JC, Rha
SY, Lee HJ, Sul JY, Kweon GR, Ro HK, et al: Influence of the BRAF
V600E mutation on expression of vascular endothelial growth factor
in papillary thyroid cancer. J Clin Endocrinol Metab. 91:3667–3670.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rusinek D, Szpak-Ulczok S and Jarzab B:
Gene expression profile of human thyroid cancer in relation to its
mutational status. J Mol Endocrinol. 47:R91–R103. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
24
|
Menzies AM and Long GV: Dabrafenib and
trametinib, alone and in combination for BRAF-mutant metastatic
melanoma. Clin Cancer Res. 20:2035–2043. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cichowski K and Jänne PA: Drug discovery:
Inhibitors that activate. Nature. 464:358–359. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fischer KR, Durrans A, Lee S, Sheng J, Li
F, Wong ST, Choi H, El Rayes T, Ryu S, Troeger J, et al:
Epithelial-to-mesenchymal transition is not required for lung
metastasis but contributes to chemoresistance. Nature. 527:472–476.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Carlino MS, Todd JR, Gowrishankar K,
Mijatov B, Pupo GM, Fung C, Snoyman S, Hersey P, Long GV, Kefford
RF, et al: Differential activity of MEK and ERK inhibitors in BRAF
inhibitor resistant melanoma. Mol Oncol. 8:544–554. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Johannessen CM, Boehm JS, Kim SY, Thomas
SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP,
Barretina J, et al: COT drives resistance to RAF inhibition through
MAP kinase pathway reactivation. Nature. 468:968–972. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nazarian R, Shi H, Wang Q, Kong X, Koya
RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, et al: Melanomas
acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS
upregulation. Nature. 468:973–977. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wagle N, Emery C, Berger MF, Davis MJ,
Sawyer A, Pochanard P, Kehoe SM, Johannessen CM, Macconaill LE,
Hahn WC, et al: Dissecting therapeutic resistance to RAF inhibition
in melanoma by tumor genomic profiling. J Clin Oncol. 29:3085–3096.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Falchook GS, Millward M, Hong D, Naing A,
Piha-Paul S, Waguespack SG, Cabanillas ME, Sherman SI, Ma B, Curtis
M, et al: BRAF inhibitor dabrafenib in patients with metastatic
BRAF-mutant thyroid cancer. Thyroid. 25:71–77. 2015. View Article : Google Scholar :
|
|
32
|
Rothenberg SM, McFadden DG, Palmer EL,
Daniels GH and Wirth LJ: Redifferentiation of iodine-refractory
BRAF V600E-mutant metastatic papillary thyroid cancer with
dabrafenib. Clin Cancer Res. 21:1028–1035. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cabanillas ME, Patel A, Danysh BP, Dadu R,
Kopetz S and Falchook G: BRAF inhibitors: Experience in thyroid
cancer and general review of toxicity. Horm Cancer. 6:21–36. 2015.
View Article : Google Scholar :
|
